Rethinking the Future of Science
The Covid-19 pandemic has had the effect of alerting the entire world to the dangers of future viruses that could wreak even more havoc. Merck Group CEO Stefan Oschmann and Pardis Sabeti, Professor of Immunology and Infectious Diseases at Harvard University, discuss how advances in medicine can help us better prepare for future medical crises. The session was moderated by LinkedIn editor Sara Weber.
Sara Weber is a German-American journalist and author. As Managing Editor DACH and Benelux at LinkedIn News, she leads the editorial teams in the German and Dutch-language regions. Sara graduated from Deutsche Journalistenschule (DJS) and previously worked as a freelance journalist.
Dr. Pardis Sabeti is a Professor of Immunology and Infectious Diseases at Harvard University. Her computational genomic lab has contributed to viral sequencing, information theory, rural disease surveillance and education efforts in West Africa. Sabeti is also a co-creator of the educational program Operation Outbreak.
Stefan Oschmann joined Merck in 2011 and has been Chairman of the Executive Board and CEO of Merck since 2016. He drove the transformation of the Biopharma business by optimizing its cost structures and improving the efficiency of its research & development model. Before joining Merck, Stefan Oschmann worked for the U.S. pharma company MSD, where he served in a range of senior executive positions.